Techniques d'exposition à la surface cellulaire : Questions médicales fréquentes
Nom anglais: Cell Surface Display Techniques
Descriptor UI:D061505
Tree Number:E05.393.420.601.292
Termes MeSH sélectionnés :
Hepatitis B virus
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Techniques d'exposition à la surface cellulaire : Questions médicales les plus fréquentes",
"headline": "Techniques d'exposition à la surface cellulaire : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Techniques d'exposition à la surface cellulaire : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-08-01",
"dateModified": "2025-04-28",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Techniques d'exposition à la surface cellulaire"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Ingénierie des protéines",
"url": "https://questionsmedicales.fr/mesh/D015202",
"about": {
"@type": "MedicalCondition",
"name": "Ingénierie des protéines",
"code": {
"@type": "MedicalCode",
"code": "D015202",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "E05.393.420.601"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Techniques d'exposition à la surface cellulaire",
"alternateName": "Cell Surface Display Techniques",
"code": {
"@type": "MedicalCode",
"code": "D061505",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Mitsuyoshi Ueda",
"url": "https://questionsmedicales.fr/author/Mitsuyoshi%20Ueda",
"affiliation": {
"@type": "Organization",
"name": "Division of Applied Life Sciences, Graduate School of Agriculture, Kyoto University, Kitashirakawa-oiwakecho, Sakyo-ku, Kyoto 606-8502, Japan."
}
},
{
"@type": "Person",
"name": "Junmei Ding",
"url": "https://questionsmedicales.fr/author/Junmei%20Ding",
"affiliation": {
"@type": "Organization",
"name": "Engineering Research Center of Sustainable Development and Utilization of Biomass Energy, Ministry of Education, Yunnan Normal University, Kunming, Yunnan, 650500, China. Electronic address: djm@ynnu.edu.cn."
}
},
{
"@type": "Person",
"name": "Jianzhen Li",
"url": "https://questionsmedicales.fr/author/Jianzhen%20Li",
"affiliation": {
"@type": "Organization",
"name": "College of Animal Husbandry and Veterinary, Chengdu Agricultural College, Chengdu, China."
}
},
{
"@type": "Person",
"name": "Abdul Khalique",
"url": "https://questionsmedicales.fr/author/Abdul%20Khalique",
"affiliation": {
"@type": "Organization",
"name": "Animal Microecology Institute, Department of Animal and Plant Quarantine, College of Veterinary Medicine, Sichuan Agricultural University, Chengdu, China."
}
},
{
"@type": "Person",
"name": "Dongmei Zhang",
"url": "https://questionsmedicales.fr/author/Dongmei%20Zhang",
"affiliation": {
"@type": "Organization",
"name": "Animal Microecology Institute, Department of Animal and Plant Quarantine, College of Veterinary Medicine, Sichuan Agricultural University, Chengdu, China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Plerixafor and resatorvid inhibit hepatitis B virus",
"datePublished": "2023-02-20",
"url": "https://questionsmedicales.fr/article/36891156",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fcimb.2023.1118801"
}
},
{
"@type": "ScholarlyArticle",
"name": "Hepatitis B Virus Research in South Africa.",
"datePublished": "2022-08-31",
"url": "https://questionsmedicales.fr/article/36146747",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/v14091939"
}
},
{
"@type": "ScholarlyArticle",
"name": "Occult Hepatitis B Virus Infection: An Update.",
"datePublished": "2022-07-08",
"url": "https://questionsmedicales.fr/article/35891484",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/v14071504"
}
},
{
"@type": "ScholarlyArticle",
"name": "Mutations in the S gene of hepatitis B virus in three generations of patients with chronic hepatitis B.",
"datePublished": "2023-06-12",
"url": "https://questionsmedicales.fr/article/37308753",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11262-023-02012-z"
}
},
{
"@type": "ScholarlyArticle",
"name": "Chronic Hepatitis B Virus: What an Internist Needs to Know: Serologic Diagnosis, Treatment Options, and Hepatitis B Virus Reactivation.",
"datePublished": "2023-02-20",
"url": "https://questionsmedicales.fr/article/37001946",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.mcna.2022.12.002"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Techniques d'investigation",
"item": "https://questionsmedicales.fr/mesh/D008919"
},
{
"@type": "ListItem",
"position": 3,
"name": "Techniques génétiques",
"item": "https://questionsmedicales.fr/mesh/D005821"
},
{
"@type": "ListItem",
"position": 4,
"name": "Génie génétique",
"item": "https://questionsmedicales.fr/mesh/D005818"
},
{
"@type": "ListItem",
"position": 5,
"name": "Ingénierie des protéines",
"item": "https://questionsmedicales.fr/mesh/D015202"
},
{
"@type": "ListItem",
"position": 6,
"name": "Techniques d'exposition à la surface cellulaire",
"item": "https://questionsmedicales.fr/mesh/D061505"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Techniques d'exposition à la surface cellulaire - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Techniques d'exposition à la surface cellulaire",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-18",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Techniques d'exposition à la surface cellulaire",
"description": "Comment les techniques d'exposition aident-elles au diagnostic ?\nQuels tests utilisent ces techniques pour le diagnostic ?\nPeut-on détecter des maladies auto-immunes avec ces techniques ?\nLes techniques d'exposition sont-elles utilisées en oncologie ?\nComment ces techniques aident-elles à identifier des pathogènes ?",
"url": "https://questionsmedicales.fr/mesh/D061505?mesh_terms=Hepatitis+B+virus&page=2#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Techniques d'exposition à la surface cellulaire",
"description": "Quels symptômes peuvent être détectés grâce à ces techniques ?\nLes symptômes d'allergies peuvent-ils être étudiés ?\nPeut-on observer des symptômes de rejet de greffe ?\nComment ces techniques aident-elles à comprendre les infections ?\nPeut-on détecter des symptômes de maladies infectieuses ?",
"url": "https://questionsmedicales.fr/mesh/D061505?mesh_terms=Hepatitis+B+virus&page=2#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Techniques d'exposition à la surface cellulaire",
"description": "Comment ces techniques contribuent-elles à la prévention des maladies ?\nPeut-on utiliser ces techniques pour des campagnes de vaccination ?\nComment ces techniques aident-elles à la recherche sur les maladies infectieuses ?\nPeut-on identifier des facteurs de risque avec ces techniques ?\nComment ces techniques aident-elles à sensibiliser le public ?",
"url": "https://questionsmedicales.fr/mesh/D061505?mesh_terms=Hepatitis+B+virus&page=2#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Techniques d'exposition à la surface cellulaire",
"description": "Comment ces techniques influencent-elles les traitements ?\nPeut-on utiliser ces techniques pour la vaccination ?\nComment ces techniques aident-elles en thérapie génique ?\nPeut-on développer des anticorps monoclonaux avec ces techniques ?\nComment ces techniques aident-elles à la recherche de nouveaux médicaments ?",
"url": "https://questionsmedicales.fr/mesh/D061505?mesh_terms=Hepatitis+B+virus&page=2#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Techniques d'exposition à la surface cellulaire",
"description": "Quelles complications peuvent survenir avec ces techniques ?\nPeut-on observer des complications en thérapie génique ?\nComment ces techniques peuvent-elles causer des effets secondaires ?\nY a-t-il des complications liées à la production d'anticorps monoclonaux ?\nComment ces techniques peuvent-elles affecter la santé à long terme ?",
"url": "https://questionsmedicales.fr/mesh/D061505?mesh_terms=Hepatitis+B+virus&page=2#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Techniques d'exposition à la surface cellulaire",
"description": "Quels facteurs de risque sont associés à l'utilisation de ces techniques ?\nL'âge influence-t-il les risques liés à ces techniques ?\nComment les maladies préexistantes affectent-elles les risques ?\nLe mode de vie influence-t-il les risques ?\nLes facteurs environnementaux jouent-ils un rôle ?",
"url": "https://questionsmedicales.fr/mesh/D061505?mesh_terms=Hepatitis+B+virus&page=2#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment les techniques d'exposition aident-elles au diagnostic ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles permettent d'analyser les interactions entre cellules et antigènes, facilitant le diagnostic immunologique."
}
},
{
"@type": "Question",
"name": "Quels tests utilisent ces techniques pour le diagnostic ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests comme l'immunofluorescence et les tests de liaison des anticorps sont courants."
}
},
{
"@type": "Question",
"name": "Peut-on détecter des maladies auto-immunes avec ces techniques ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles aident à identifier des auto-anticorps spécifiques dans les maladies auto-immunes."
}
},
{
"@type": "Question",
"name": "Les techniques d'exposition sont-elles utilisées en oncologie ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles permettent de détecter des marqueurs tumoraux sur les cellules cancéreuses."
}
},
{
"@type": "Question",
"name": "Comment ces techniques aident-elles à identifier des pathogènes ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles permettent de visualiser l'interaction entre les cellules immunitaires et les pathogènes."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent être détectés grâce à ces techniques ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles aident à identifier des réponses immunitaires anormales, comme des inflammations."
}
},
{
"@type": "Question",
"name": "Les symptômes d'allergies peuvent-ils être étudiés ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles permettent d'analyser les réponses allergiques en exposant des allergènes."
}
},
{
"@type": "Question",
"name": "Peut-on observer des symptômes de rejet de greffe ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ces techniques aident à étudier les interactions entre cellules greffées et hôtes."
}
},
{
"@type": "Question",
"name": "Comment ces techniques aident-elles à comprendre les infections ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles permettent d'observer les réponses des cellules face à des infections virales ou bactériennes."
}
},
{
"@type": "Question",
"name": "Peut-on détecter des symptômes de maladies infectieuses ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles aident à identifier des marqueurs spécifiques de maladies infectieuses sur les cellules."
}
},
{
"@type": "Question",
"name": "Comment ces techniques contribuent-elles à la prévention des maladies ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles aident à identifier des biomarqueurs pour le dépistage précoce de maladies."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser ces techniques pour des campagnes de vaccination ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles permettent de mieux cibler les populations à risque pour les vaccinations."
}
},
{
"@type": "Question",
"name": "Comment ces techniques aident-elles à la recherche sur les maladies infectieuses ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles permettent d'étudier les mécanismes d'infection et de développer des stratégies préventives."
}
},
{
"@type": "Question",
"name": "Peut-on identifier des facteurs de risque avec ces techniques ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles aident à déterminer des facteurs de risque immunologiques pour certaines maladies."
}
},
{
"@type": "Question",
"name": "Comment ces techniques aident-elles à sensibiliser le public ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles fournissent des données sur les réponses immunitaires, utiles pour l'éducation sanitaire."
}
},
{
"@type": "Question",
"name": "Comment ces techniques influencent-elles les traitements ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles permettent de développer des thérapies ciblées en étudiant les interactions cellulaires."
}
},
{
"@type": "Question",
"name": "Peut-on utiliser ces techniques pour la vaccination ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles aident à concevoir des vaccins en exposant des antigènes sur des cellules immunitaires."
}
},
{
"@type": "Question",
"name": "Comment ces techniques aident-elles en thérapie génique ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles permettent de cibler des cellules spécifiques pour introduire des gènes thérapeutiques."
}
},
{
"@type": "Question",
"name": "Peut-on développer des anticorps monoclonaux avec ces techniques ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles sont essentielles pour produire des anticorps monoclonaux en exposant des antigènes."
}
},
{
"@type": "Question",
"name": "Comment ces techniques aident-elles à la recherche de nouveaux médicaments ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles permettent de tester l'efficacité de nouveaux composés sur des cellules spécifiques."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec ces techniques ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des réactions indésirables peuvent se produire lors de l'exposition à des antigènes."
}
},
{
"@type": "Question",
"name": "Peut-on observer des complications en thérapie génique ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications immunologiques peuvent survenir lors de l'introduction de gènes."
}
},
{
"@type": "Question",
"name": "Comment ces techniques peuvent-elles causer des effets secondaires ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent induire des réponses immunitaires non spécifiques, entraînant des effets secondaires."
}
},
{
"@type": "Question",
"name": "Y a-t-il des complications liées à la production d'anticorps monoclonaux ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications peuvent survenir lors de l'administration d'anticorps monoclonaux."
}
},
{
"@type": "Question",
"name": "Comment ces techniques peuvent-elles affecter la santé à long terme ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des effets à long terme sur le système immunitaire peuvent être observés après exposition répétée."
}
},
{
"@type": "Question",
"name": "Quels facteurs de risque sont associés à l'utilisation de ces techniques ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antécédents d'allergies ou d'auto-immunité peuvent augmenter les risques."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il les risques liés à ces techniques ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les personnes âgées peuvent avoir des réponses immunitaires altérées, augmentant les risques."
}
},
{
"@type": "Question",
"name": "Comment les maladies préexistantes affectent-elles les risques ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les maladies préexistantes peuvent exacerber les réactions indésirables aux antigènes."
}
},
{
"@type": "Question",
"name": "Le mode de vie influence-t-il les risques ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un mode de vie malsain peut compromettre le système immunitaire, augmentant les risques."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux jouent-ils un rôle ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des toxines environnementales peut influencer les réponses immunitaires."
}
}
]
}
]
}
An increase in the demand for a functional cure has accelerated research on new methods of therapy for chronic hepatitis B, which is mainly focused on restoring antiviral immunity for controlling vira...
In this study, we generated the Epro-LUC-HepG2 cell model for screening compounds that target EFTUD2. Plerixafor and resatorvid were screened from 261 immunity and inflammation-related compounds due t...
The dual-luciferase reporter assays showed that the EFTUD2 promoter hEFTUD2pro-0.5 kb had the strongest activity. In Epro-LUC-HepG2 cells, plerixafor and resatorvid significantly upregulated the activ...
We established a convenient model for screening compounds that target EFTUD2 and further identified plerixafor and resatorvid as novel HBV inhibitors...
Despite being vaccine-preventable, hepatitis B virus (HBV) infection remains the seventh leading cause of mortality in the world. In South Africa (SA), over 1.9 million people are chronically infected...
Occult hepatitis B virus (HBV) infection (OBI) refers to a condition in which replication-competent viral DNA is present in the liver (with detectable or undetectable HBV DNA in the serum) of individu...
Failure to neutralize HBsAg and subsequent escape from the host immune system may be caused by HBsAg mutations, particularly in the "a" determinant, which alters the antigenicity of the protein. The p...
Chronic hepatitis B virus (HBV) infection is a bloodborne infection which affects approximately 1.6 million persons in the U.S. and 292 million persons worldwide and is associated with significant mor...
Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor approved for the treatment for several mature B-cell malignancies. Reactivation of hepatitis B virus (HBV) is a well-described complication in p...
We report the first case of HBV reactivation during ibrutinib treatment in an asymptomatic 82-year-old woman with seronegative occult hepatitis B patient (i.e., negative for HBsAg, anti-HBc and anti-H...
Our case illustrated that in populations with a high incidence of HBV exposure, systematic screening for HBV exposure is essential prior to ibrutinib treatment, followed by serial monitoring of serolo...
There is no effective treatment for occult hepatitis B virus infection (OBI) patients, and immunotherapy may be one of the most promising options. We aim to investigate the underlying mechanism and th...
Outpatient OBI patients were screened and randomly divided into treatment (Group A) and control (Group B) groups. At weeks 0, 4, and 24, patients in Group A received a subcutaneous/intramuscular injec...
Of the 228 OBI patients, 28 were excluded, and 200 were enrolled for observation. In the end, 44 patients were included in Group A and 39 in Group B after excluding lost cases. At week 0 (baseline), s...
Anti-HBs in Group A patients were positively correlated with B lymphocytes (r=0.3431, 0.3087, and 0.3041, respectively) and positively correlated with CD8...
Virological reactivation is a risk for OBI patients. Serum hepatitis B surface antibodies were significantly increased after hepatitis B vaccine treatment, the same as the numbers of peripheral blood ...
Donors with resolved hepatitis B virus (HBV) infection may be a solution for the organ shortage for kidney transplantation (KT). The purpose of this study was to clarify the current state of HBV marke...
The immunologic features involved in the immune-tolerant phase of chronic hepatitis B (CHB) virus (HBV) infection are unclear. The hepatitis B virus X (HBx) protein disrupts IFN-β induction by downreg...
Children with CHB in the immune-tolerant phase were recruited and followed longitudinally. HBx gene sequencing of infecting HBV strains was performed, and the effects of HBx mutations on the immune-to...
A total of 173 children (median age, 6.92 years) were recruited. Patients carrying HBx R87G, I127V and R87G + I127V double mutations exhibited higher cumulative incidences of immune-tolerant phase bre...
HBx suppresses IFN-β induction. R87G and I127V mutation restored IFN-β production by preventing MAVS degradation, contributing to curtailing the HBV immune-tolerant phase in CHB patients....
Hepatitis B virus (HBV)-human Immunodeficiency virus (HIV) co-infection promotes an aggressive disease course of HBV infection. In the only available non-Cochrane systematic review on antiviral therap...
To evaluate the benefits and harms of tenofovir-based antiviral combination regimens versus placebo, tenofovir alone, or non-tenofovir-based antiviral regimen either alone or in combination with HBV f...
We searched the Cochrane Hepato-Biliary Group Controlled Trials Register, Cochrane Central Register of Controlled Trials, MEDLINE Ovid, Embase Ovid, LILACS (Bireme), Science Citation Index Expanded (W...
We aimed to include randomised clinical trials comparing tenofovir-based antiviral combination regimens (anti-HIV regimen with lopinavir-ritonavir therapy, or any other antiviral therapy, and two drug...
We used standard methodological procedures expected by Cochrane. Primary outcomes included all-cause infant mortality, proportion of infants with serious adverse events, proportion of infants with HBV...
Five completed trials were included, of which four trials contributed data to one or more of the outcomes. They included a total of 533 participants randomised to tenofovir-based antiviral combination...
We do not know what the effects of tenofovir-based antiviral combination regimens are on all-cause infant mortality, proportion of infants with serious adverse events and proportion of mothers with se...